Neuroinflammation /:
Neuroinflammation, Second Edition, discusses the role inflammation plays in neuro-inflammatory diseases. As research in neuroinflammation has dramatically increased in recent years, this new edition covers all of the new developments and findings since the first publication nearly a decade ago. Comp...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
London :
Academic Press, an imprint of Elsevier,
[2018]
|
| Ausgabe: | Second edition. |
| Schlagworte: | |
| Online-Zugang: | Volltext Volltext |
| Zusammenfassung: | Neuroinflammation, Second Edition, discusses the role inflammation plays in neuro-inflammatory diseases. As research in neuroinflammation has dramatically increased in recent years, this new edition covers all of the new developments and findings since the first publication nearly a decade ago. Comprehensive coverage of topics includes chapters on multiple sclerosis, optic neuritis and Susac syndrome. New chapters cover the latest research in Epilepsy and Neuroinflammation, Pediatric MS, Pediatric Lupus and Traumatic Brain Injury, amongst other topics. Inflammation is a central mechanism in many neurological diseases, including stroke, multiple sclerosis, brain trauma and meningitis, and it contributes to the generation of pain. Researchers are now beginning to understand the impact of the immune system on different nervous system functions and diseases, ranging from damage, through tolerance, and to modulation and repair. |
| Beschreibung: | 1 online resource |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9780128117248 0128117249 9780128117095 0128117095 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1047959805 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 180807s2018 enk ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d OPELS |d EBLCP |d YDX |d OCLCF |d NLE |d UAB |d STF |d DKU |d MERUC |d MERER |d IAY |d UKMGB |d ESU |d OTZ |d U3W |d LVT |d DEBBG |d D6H |d SNK |d COO |d AU@ |d DCT |d ERF |d UHL |d OCLCQ |d S2H |d OCLCO |d UX1 |d VT2 |d OCLCA |d OCLCQ |d OCLCO |d K6U |d OCLCQ |d SFB |d OCLCQ |d OCLCO |d OCLCL |d OCLCQ | ||
| 066 | |c (S | ||
| 015 | |a GBB8G7086 |2 bnb | ||
| 016 | 7 | |a 019004795 |2 Uk | |
| 019 | |a 1048290263 |a 1235838122 | ||
| 020 | |a 9780128117248 |q (electronic bk.) | ||
| 020 | |a 0128117249 |q (electronic bk.) | ||
| 020 | |a 9780128117095 |q (electronic bk.) | ||
| 020 | |a 0128117095 |q (electronic bk.) | ||
| 035 | |a (OCoLC)1047959805 |z (OCoLC)1048290263 |z (OCoLC)1235838122 | ||
| 037 | |a 9780128117248 |b Ingram Content Group | ||
| 050 | 4 | |a RC346 | |
| 060 | 4 | |a 2018 H-749 | |
| 060 | 4 | |a WL 140 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 072 | 7 | |a PSAN |2 bicssc | |
| 082 | 7 | |a 616.8047 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Neuroinflammation / |c edited by Alireza Minagar. |
| 250 | |a Second edition. | ||
| 264 | 1 | |a London : |b Academic Press, an imprint of Elsevier, |c [2018] | |
| 264 | 4 | |c ©2018 | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed August 08, 2018). | |
| 520 | |a Neuroinflammation, Second Edition, discusses the role inflammation plays in neuro-inflammatory diseases. As research in neuroinflammation has dramatically increased in recent years, this new edition covers all of the new developments and findings since the first publication nearly a decade ago. Comprehensive coverage of topics includes chapters on multiple sclerosis, optic neuritis and Susac syndrome. New chapters cover the latest research in Epilepsy and Neuroinflammation, Pediatric MS, Pediatric Lupus and Traumatic Brain Injury, amongst other topics. Inflammation is a central mechanism in many neurological diseases, including stroke, multiple sclerosis, brain trauma and meningitis, and it contributes to the generation of pain. Researchers are now beginning to understand the impact of the immune system on different nervous system functions and diseases, ranging from damage, through tolerance, and to modulation and repair. | ||
| 505 | 0 | |a Front Cover; Neuroinflammation; Copyright Page; Contents; List of Contributors; Preface; 1 Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management; Clinical Features; Initial Presentation of MS; Clinical Course of MS; MS-Exacerbating Conditions; Pathophysiology; Pathophysiology of Relapses and Disease Progression; "Inflammation" in MS Pathophysiology; "Degeneration" in MS Pathophysiology; Inflammation-Induced Degenerative Processes; Primary Degenerative Processes; Pathophysiology of Remissions; Pathophysiology of Cortical Manifestations; Diagnosis; Management | |
| 505 | 8 | |a NAb Titer and Defining NAb StatusClinical Relevance of NAbs; Clinical Outcomes; MRI Outcomes; NAbs Testing in Clinical Practice; Glatiramer Acetate; Natalizumab; Conclusion; References; 3 Animal Models of Multiple Sclerosis; Etiology, Clinical Course, and Pathology; Etiologies of MS and Its Animal Models; Animal Models: EAE and TMEV Infection; Clinical Courses of MS and Its Animal Models; Pathology of MS and Its Animal Models; Demyelination Versus Axonal Degeneration (Neurodegeneration): Inside-Out Model of MS; CD4+ T-cells in MS and Its Animal Models; Th Cell Subsets | |
| 505 | 8 | |a Roles of Th1 Cells in EAE and TMEV InfectionRoles of Th2 Cells in EAE and TMEV Infection; Roles of Th17 Cells in EAE and TMEV Infection; Roles of Tregs in EAE and TMEV Infection; Chemokines and Chemokine Receptors in MS and Its Animal Models; Chemokines and Chemokine Receptors; CXCR3 and Its Ligands in MS, EAE, and TMEV Infection; CCR5 and Its Ligands in MS, EAE, and TMEV Infection; CCR2 and Its Ligands in MS, EAE, and TMEV Infection; CCR4 and Its Ligands in MS and EAE; CCR6 and Its Ligands in MS and EAE; Future Perspectives | |
| 505 | 8 | |a MS Heterogeneities Explain the Differing Roles of Th Cell Subsets and Chemokine ReceptorsChemokines and Chemokine Receptors as a Potential Target for MS Treatment; Acknowledgments; References; 4 Neuroimaging of Multiple Sclerosis and Other Immune-Mediated Diseases of Central Nervous System: An Update; Introduction; Imaging of Multiple Sclerosis; Conventional Imaging; Imaging Findings; Nonconventional Imaging Techniques in the Differential Diagnosis of MS; Susceptibility-Weighted Imaging; Perfusion Imaging; MR Spectroscopy; Diffusion Tensor Imaging; Radiologically Isolated Syndrome (RIS) | |
| 650 | 0 | |a Nervous system |x Diseases. |0 http://id.loc.gov/authorities/subjects/sh85090924 | |
| 650 | 0 | |a Nervous system |x Degeneration. |0 http://id.loc.gov/authorities/subjects/sh85090923 | |
| 650 | 0 | |a Multiple sclerosis. |0 http://id.loc.gov/authorities/subjects/sh85088374 | |
| 650 | 0 | |a Inflammation. |0 http://id.loc.gov/authorities/subjects/sh85066108 | |
| 650 | 1 | 2 | |a Nervous System Diseases |
| 650 | 2 | 2 | |a Inflammation |x physiopathology |0 https://id.nlm.nih.gov/mesh/D007249Q000503 |
| 650 | 2 | 2 | |a Nerve Degeneration |x immunology |0 https://id.nlm.nih.gov/mesh/D009410Q000276 |
| 650 | 2 | |a Multiple Sclerosis |0 https://id.nlm.nih.gov/mesh/D009103 | |
| 650 | 2 | |a Inflammation |0 https://id.nlm.nih.gov/mesh/D007249 | |
| 650 | 6 | |a Système nerveux |x Maladies. | |
| 650 | 6 | |a Sclérose en plaques. | |
| 650 | 6 | |a Inflammation (Pathologie) | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Inflammation |2 fast | |
| 650 | 7 | |a Multiple sclerosis |2 fast | |
| 650 | 7 | |a Nervous system |x Degeneration |2 fast | |
| 650 | 7 | |a Nervous system |x Diseases |2 fast | |
| 700 | 1 | |a Minagar, Alireza, |e editor. |0 http://id.loc.gov/authorities/names/n2004122915 | |
| 776 | 0 | 8 | |i Print version: |t Neuroinflammation. |b Second edition. |d London : Academic Press, an imprint of Elsevier, [2018] |z 0128117095 |z 9780128117095 |w (OCoLC)1011515169 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://www.sciencedirect.com/science/book/9780128117095 |3 Volltext |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1703359 |3 Volltext |
| 880 | 8 | |6 505-00/(S |a Management of Acute RelapsesDisease-Modifying Therapies; Interferon-Beta; Glatiramer Acetate; Dimethyl Fumarate; Teriflunomide; Fingolimod; Natalizumab; Alemtuzumab; Daclizumab; References; Further Reading; 2 Neutralizing Antibodies and Multiple Sclerosis in the Era of Disease Modifying Treatments; Introduction; Interferon Beta; Immunogenicity; Neutralizing Antibody Assays; The Cytopathic Effect (CPE) Assay; Assays Based on the Interferon-β-Stimulated Production of Myxovirus Resistance Protein A; The Reporter Gene Assay; The In Vivo Induction of Myxovirus Resistance Protein A | |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL5484205 | ||
| 938 | |a EBSCOhost |b EBSC |n 1703359 | ||
| 938 | |a YBP Library Services |b YANK |n 15631746 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1047959805 |
|---|---|
| _version_ | 1816882467676618752 |
| adam_text | |
| any_adam_object | |
| author2 | Minagar, Alireza |
| author2_role | edt |
| author2_variant | a m am |
| author_GND | http://id.loc.gov/authorities/names/n2004122915 |
| author_facet | Minagar, Alireza |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC346 |
| callnumber-raw | RC346 |
| callnumber-search | RC346 |
| callnumber-sort | RC 3346 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Front Cover; Neuroinflammation; Copyright Page; Contents; List of Contributors; Preface; 1 Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management; Clinical Features; Initial Presentation of MS; Clinical Course of MS; MS-Exacerbating Conditions; Pathophysiology; Pathophysiology of Relapses and Disease Progression; "Inflammation" in MS Pathophysiology; "Degeneration" in MS Pathophysiology; Inflammation-Induced Degenerative Processes; Primary Degenerative Processes; Pathophysiology of Remissions; Pathophysiology of Cortical Manifestations; Diagnosis; Management NAb Titer and Defining NAb StatusClinical Relevance of NAbs; Clinical Outcomes; MRI Outcomes; NAbs Testing in Clinical Practice; Glatiramer Acetate; Natalizumab; Conclusion; References; 3 Animal Models of Multiple Sclerosis; Etiology, Clinical Course, and Pathology; Etiologies of MS and Its Animal Models; Animal Models: EAE and TMEV Infection; Clinical Courses of MS and Its Animal Models; Pathology of MS and Its Animal Models; Demyelination Versus Axonal Degeneration (Neurodegeneration): Inside-Out Model of MS; CD4+ T-cells in MS and Its Animal Models; Th Cell Subsets Roles of Th1 Cells in EAE and TMEV InfectionRoles of Th2 Cells in EAE and TMEV Infection; Roles of Th17 Cells in EAE and TMEV Infection; Roles of Tregs in EAE and TMEV Infection; Chemokines and Chemokine Receptors in MS and Its Animal Models; Chemokines and Chemokine Receptors; CXCR3 and Its Ligands in MS, EAE, and TMEV Infection; CCR5 and Its Ligands in MS, EAE, and TMEV Infection; CCR2 and Its Ligands in MS, EAE, and TMEV Infection; CCR4 and Its Ligands in MS and EAE; CCR6 and Its Ligands in MS and EAE; Future Perspectives MS Heterogeneities Explain the Differing Roles of Th Cell Subsets and Chemokine ReceptorsChemokines and Chemokine Receptors as a Potential Target for MS Treatment; Acknowledgments; References; 4 Neuroimaging of Multiple Sclerosis and Other Immune-Mediated Diseases of Central Nervous System: An Update; Introduction; Imaging of Multiple Sclerosis; Conventional Imaging; Imaging Findings; Nonconventional Imaging Techniques in the Differential Diagnosis of MS; Susceptibility-Weighted Imaging; Perfusion Imaging; MR Spectroscopy; Diffusion Tensor Imaging; Radiologically Isolated Syndrome (RIS) |
| ctrlnum | (OCoLC)1047959805 |
| dewey-full | 616.8047 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.8047 |
| dewey-search | 616.8047 |
| dewey-sort | 3616.8047 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | Second edition. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>07573cam a2200901 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1047959805</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu|||unuuu</controlfield><controlfield tag="008">180807s2018 enk ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">N$T</subfield><subfield code="d">OPELS</subfield><subfield code="d">EBLCP</subfield><subfield code="d">YDX</subfield><subfield code="d">OCLCF</subfield><subfield code="d">NLE</subfield><subfield code="d">UAB</subfield><subfield code="d">STF</subfield><subfield code="d">DKU</subfield><subfield code="d">MERUC</subfield><subfield code="d">MERER</subfield><subfield code="d">IAY</subfield><subfield code="d">UKMGB</subfield><subfield code="d">ESU</subfield><subfield code="d">OTZ</subfield><subfield code="d">U3W</subfield><subfield code="d">LVT</subfield><subfield code="d">DEBBG</subfield><subfield code="d">D6H</subfield><subfield code="d">SNK</subfield><subfield code="d">COO</subfield><subfield code="d">AU@</subfield><subfield code="d">DCT</subfield><subfield code="d">ERF</subfield><subfield code="d">UHL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">S2H</subfield><subfield code="d">OCLCO</subfield><subfield code="d">UX1</subfield><subfield code="d">VT2</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">SFB</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="066" ind1=" " ind2=" "><subfield code="c">(S</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBB8G7086</subfield><subfield code="2">bnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">019004795</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1048290263</subfield><subfield code="a">1235838122</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780128117248</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0128117249</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780128117095</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0128117095</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1047959805</subfield><subfield code="z">(OCoLC)1048290263</subfield><subfield code="z">(OCoLC)1235838122</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">9780128117248</subfield><subfield code="b">Ingram Content Group</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC346</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">2018 H-749</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">WL 140</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">014000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">022000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">112000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">045000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">PSAN</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.8047</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Neuroinflammation /</subfield><subfield code="c">edited by Alireza Minagar.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">Second edition.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London :</subfield><subfield code="b">Academic Press, an imprint of Elsevier,</subfield><subfield code="c">[2018]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from PDF title page (EBSCO, viewed August 08, 2018).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neuroinflammation, Second Edition, discusses the role inflammation plays in neuro-inflammatory diseases. As research in neuroinflammation has dramatically increased in recent years, this new edition covers all of the new developments and findings since the first publication nearly a decade ago. Comprehensive coverage of topics includes chapters on multiple sclerosis, optic neuritis and Susac syndrome. New chapters cover the latest research in Epilepsy and Neuroinflammation, Pediatric MS, Pediatric Lupus and Traumatic Brain Injury, amongst other topics. Inflammation is a central mechanism in many neurological diseases, including stroke, multiple sclerosis, brain trauma and meningitis, and it contributes to the generation of pain. Researchers are now beginning to understand the impact of the immune system on different nervous system functions and diseases, ranging from damage, through tolerance, and to modulation and repair.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Front Cover; Neuroinflammation; Copyright Page; Contents; List of Contributors; Preface; 1 Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management; Clinical Features; Initial Presentation of MS; Clinical Course of MS; MS-Exacerbating Conditions; Pathophysiology; Pathophysiology of Relapses and Disease Progression; "Inflammation" in MS Pathophysiology; "Degeneration" in MS Pathophysiology; Inflammation-Induced Degenerative Processes; Primary Degenerative Processes; Pathophysiology of Remissions; Pathophysiology of Cortical Manifestations; Diagnosis; Management</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">NAb Titer and Defining NAb StatusClinical Relevance of NAbs; Clinical Outcomes; MRI Outcomes; NAbs Testing in Clinical Practice; Glatiramer Acetate; Natalizumab; Conclusion; References; 3 Animal Models of Multiple Sclerosis; Etiology, Clinical Course, and Pathology; Etiologies of MS and Its Animal Models; Animal Models: EAE and TMEV Infection; Clinical Courses of MS and Its Animal Models; Pathology of MS and Its Animal Models; Demyelination Versus Axonal Degeneration (Neurodegeneration): Inside-Out Model of MS; CD4+ T-cells in MS and Its Animal Models; Th Cell Subsets</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Roles of Th1 Cells in EAE and TMEV InfectionRoles of Th2 Cells in EAE and TMEV Infection; Roles of Th17 Cells in EAE and TMEV Infection; Roles of Tregs in EAE and TMEV Infection; Chemokines and Chemokine Receptors in MS and Its Animal Models; Chemokines and Chemokine Receptors; CXCR3 and Its Ligands in MS, EAE, and TMEV Infection; CCR5 and Its Ligands in MS, EAE, and TMEV Infection; CCR2 and Its Ligands in MS, EAE, and TMEV Infection; CCR4 and Its Ligands in MS and EAE; CCR6 and Its Ligands in MS and EAE; Future Perspectives</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">MS Heterogeneities Explain the Differing Roles of Th Cell Subsets and Chemokine ReceptorsChemokines and Chemokine Receptors as a Potential Target for MS Treatment; Acknowledgments; References; 4 Neuroimaging of Multiple Sclerosis and Other Immune-Mediated Diseases of Central Nervous System: An Update; Introduction; Imaging of Multiple Sclerosis; Conventional Imaging; Imaging Findings; Nonconventional Imaging Techniques in the Differential Diagnosis of MS; Susceptibility-Weighted Imaging; Perfusion Imaging; MR Spectroscopy; Diffusion Tensor Imaging; Radiologically Isolated Syndrome (RIS)</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Nervous system</subfield><subfield code="x">Diseases.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85090924</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Nervous system</subfield><subfield code="x">Degeneration.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85090923</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Multiple sclerosis.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85088374</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Inflammation.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85066108</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Nervous System Diseases</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Inflammation</subfield><subfield code="x">physiopathology</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D007249Q000503</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Nerve Degeneration</subfield><subfield code="x">immunology</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D009410Q000276</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Multiple Sclerosis</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D009103</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Inflammation</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D007249</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Système nerveux</subfield><subfield code="x">Maladies.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Sclérose en plaques.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Inflammation (Pathologie)</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">General.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Clinical Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Diseases.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Evidence-Based Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Internal Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inflammation</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Multiple sclerosis</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nervous system</subfield><subfield code="x">Degeneration</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nervous system</subfield><subfield code="x">Diseases</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Minagar, Alireza,</subfield><subfield code="e">editor.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2004122915</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Neuroinflammation.</subfield><subfield code="b">Second edition.</subfield><subfield code="d">London : Academic Press, an imprint of Elsevier, [2018]</subfield><subfield code="z">0128117095</subfield><subfield code="z">9780128117095</subfield><subfield code="w">(OCoLC)1011515169</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://www.sciencedirect.com/science/book/9780128117095</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1703359</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="880" ind1="8" ind2=" "><subfield code="6">505-00/(S</subfield><subfield code="a">Management of Acute RelapsesDisease-Modifying Therapies; Interferon-Beta; Glatiramer Acetate; Dimethyl Fumarate; Teriflunomide; Fingolimod; Natalizumab; Alemtuzumab; Daclizumab; References; Further Reading; 2 Neutralizing Antibodies and Multiple Sclerosis in the Era of Disease Modifying Treatments; Introduction; Interferon Beta; Immunogenicity; Neutralizing Antibody Assays; The Cytopathic Effect (CPE) Assay; Assays Based on the Interferon-β-Stimulated Production of Myxovirus Resistance Protein A; The Reporter Gene Assay; The In Vivo Induction of Myxovirus Resistance Protein A</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL5484205</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1703359</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">15631746</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1047959805 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:29:05Z |
| institution | BVB |
| isbn | 9780128117248 0128117249 9780128117095 0128117095 |
| language | English |
| oclc_num | 1047959805 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource |
| psigel | ZDB-4-EBA |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | Academic Press, an imprint of Elsevier, |
| record_format | marc |
| spelling | Neuroinflammation / edited by Alireza Minagar. Second edition. London : Academic Press, an imprint of Elsevier, [2018] ©2018 1 online resource text txt rdacontent computer c rdamedia online resource cr rdacarrier Includes bibliographical references and index. Online resource; title from PDF title page (EBSCO, viewed August 08, 2018). Neuroinflammation, Second Edition, discusses the role inflammation plays in neuro-inflammatory diseases. As research in neuroinflammation has dramatically increased in recent years, this new edition covers all of the new developments and findings since the first publication nearly a decade ago. Comprehensive coverage of topics includes chapters on multiple sclerosis, optic neuritis and Susac syndrome. New chapters cover the latest research in Epilepsy and Neuroinflammation, Pediatric MS, Pediatric Lupus and Traumatic Brain Injury, amongst other topics. Inflammation is a central mechanism in many neurological diseases, including stroke, multiple sclerosis, brain trauma and meningitis, and it contributes to the generation of pain. Researchers are now beginning to understand the impact of the immune system on different nervous system functions and diseases, ranging from damage, through tolerance, and to modulation and repair. Front Cover; Neuroinflammation; Copyright Page; Contents; List of Contributors; Preface; 1 Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management; Clinical Features; Initial Presentation of MS; Clinical Course of MS; MS-Exacerbating Conditions; Pathophysiology; Pathophysiology of Relapses and Disease Progression; "Inflammation" in MS Pathophysiology; "Degeneration" in MS Pathophysiology; Inflammation-Induced Degenerative Processes; Primary Degenerative Processes; Pathophysiology of Remissions; Pathophysiology of Cortical Manifestations; Diagnosis; Management NAb Titer and Defining NAb StatusClinical Relevance of NAbs; Clinical Outcomes; MRI Outcomes; NAbs Testing in Clinical Practice; Glatiramer Acetate; Natalizumab; Conclusion; References; 3 Animal Models of Multiple Sclerosis; Etiology, Clinical Course, and Pathology; Etiologies of MS and Its Animal Models; Animal Models: EAE and TMEV Infection; Clinical Courses of MS and Its Animal Models; Pathology of MS and Its Animal Models; Demyelination Versus Axonal Degeneration (Neurodegeneration): Inside-Out Model of MS; CD4+ T-cells in MS and Its Animal Models; Th Cell Subsets Roles of Th1 Cells in EAE and TMEV InfectionRoles of Th2 Cells in EAE and TMEV Infection; Roles of Th17 Cells in EAE and TMEV Infection; Roles of Tregs in EAE and TMEV Infection; Chemokines and Chemokine Receptors in MS and Its Animal Models; Chemokines and Chemokine Receptors; CXCR3 and Its Ligands in MS, EAE, and TMEV Infection; CCR5 and Its Ligands in MS, EAE, and TMEV Infection; CCR2 and Its Ligands in MS, EAE, and TMEV Infection; CCR4 and Its Ligands in MS and EAE; CCR6 and Its Ligands in MS and EAE; Future Perspectives MS Heterogeneities Explain the Differing Roles of Th Cell Subsets and Chemokine ReceptorsChemokines and Chemokine Receptors as a Potential Target for MS Treatment; Acknowledgments; References; 4 Neuroimaging of Multiple Sclerosis and Other Immune-Mediated Diseases of Central Nervous System: An Update; Introduction; Imaging of Multiple Sclerosis; Conventional Imaging; Imaging Findings; Nonconventional Imaging Techniques in the Differential Diagnosis of MS; Susceptibility-Weighted Imaging; Perfusion Imaging; MR Spectroscopy; Diffusion Tensor Imaging; Radiologically Isolated Syndrome (RIS) Nervous system Diseases. http://id.loc.gov/authorities/subjects/sh85090924 Nervous system Degeneration. http://id.loc.gov/authorities/subjects/sh85090923 Multiple sclerosis. http://id.loc.gov/authorities/subjects/sh85088374 Inflammation. http://id.loc.gov/authorities/subjects/sh85066108 Nervous System Diseases Inflammation physiopathology https://id.nlm.nih.gov/mesh/D007249Q000503 Nerve Degeneration immunology https://id.nlm.nih.gov/mesh/D009410Q000276 Multiple Sclerosis https://id.nlm.nih.gov/mesh/D009103 Inflammation https://id.nlm.nih.gov/mesh/D007249 Système nerveux Maladies. Sclérose en plaques. Inflammation (Pathologie) HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Inflammation fast Multiple sclerosis fast Nervous system Degeneration fast Nervous system Diseases fast Minagar, Alireza, editor. http://id.loc.gov/authorities/names/n2004122915 Print version: Neuroinflammation. Second edition. London : Academic Press, an imprint of Elsevier, [2018] 0128117095 9780128117095 (OCoLC)1011515169 FWS01 ZDB-4-EBA FWS_PDA_EBA https://www.sciencedirect.com/science/book/9780128117095 Volltext FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1703359 Volltext 505-00/(S Management of Acute RelapsesDisease-Modifying Therapies; Interferon-Beta; Glatiramer Acetate; Dimethyl Fumarate; Teriflunomide; Fingolimod; Natalizumab; Alemtuzumab; Daclizumab; References; Further Reading; 2 Neutralizing Antibodies and Multiple Sclerosis in the Era of Disease Modifying Treatments; Introduction; Interferon Beta; Immunogenicity; Neutralizing Antibody Assays; The Cytopathic Effect (CPE) Assay; Assays Based on the Interferon-β-Stimulated Production of Myxovirus Resistance Protein A; The Reporter Gene Assay; The In Vivo Induction of Myxovirus Resistance Protein A |
| spellingShingle | Neuroinflammation / Front Cover; Neuroinflammation; Copyright Page; Contents; List of Contributors; Preface; 1 Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management; Clinical Features; Initial Presentation of MS; Clinical Course of MS; MS-Exacerbating Conditions; Pathophysiology; Pathophysiology of Relapses and Disease Progression; "Inflammation" in MS Pathophysiology; "Degeneration" in MS Pathophysiology; Inflammation-Induced Degenerative Processes; Primary Degenerative Processes; Pathophysiology of Remissions; Pathophysiology of Cortical Manifestations; Diagnosis; Management NAb Titer and Defining NAb StatusClinical Relevance of NAbs; Clinical Outcomes; MRI Outcomes; NAbs Testing in Clinical Practice; Glatiramer Acetate; Natalizumab; Conclusion; References; 3 Animal Models of Multiple Sclerosis; Etiology, Clinical Course, and Pathology; Etiologies of MS and Its Animal Models; Animal Models: EAE and TMEV Infection; Clinical Courses of MS and Its Animal Models; Pathology of MS and Its Animal Models; Demyelination Versus Axonal Degeneration (Neurodegeneration): Inside-Out Model of MS; CD4+ T-cells in MS and Its Animal Models; Th Cell Subsets Roles of Th1 Cells in EAE and TMEV InfectionRoles of Th2 Cells in EAE and TMEV Infection; Roles of Th17 Cells in EAE and TMEV Infection; Roles of Tregs in EAE and TMEV Infection; Chemokines and Chemokine Receptors in MS and Its Animal Models; Chemokines and Chemokine Receptors; CXCR3 and Its Ligands in MS, EAE, and TMEV Infection; CCR5 and Its Ligands in MS, EAE, and TMEV Infection; CCR2 and Its Ligands in MS, EAE, and TMEV Infection; CCR4 and Its Ligands in MS and EAE; CCR6 and Its Ligands in MS and EAE; Future Perspectives MS Heterogeneities Explain the Differing Roles of Th Cell Subsets and Chemokine ReceptorsChemokines and Chemokine Receptors as a Potential Target for MS Treatment; Acknowledgments; References; 4 Neuroimaging of Multiple Sclerosis and Other Immune-Mediated Diseases of Central Nervous System: An Update; Introduction; Imaging of Multiple Sclerosis; Conventional Imaging; Imaging Findings; Nonconventional Imaging Techniques in the Differential Diagnosis of MS; Susceptibility-Weighted Imaging; Perfusion Imaging; MR Spectroscopy; Diffusion Tensor Imaging; Radiologically Isolated Syndrome (RIS) Nervous system Diseases. http://id.loc.gov/authorities/subjects/sh85090924 Nervous system Degeneration. http://id.loc.gov/authorities/subjects/sh85090923 Multiple sclerosis. http://id.loc.gov/authorities/subjects/sh85088374 Inflammation. http://id.loc.gov/authorities/subjects/sh85066108 Nervous System Diseases Inflammation physiopathology https://id.nlm.nih.gov/mesh/D007249Q000503 Nerve Degeneration immunology https://id.nlm.nih.gov/mesh/D009410Q000276 Multiple Sclerosis https://id.nlm.nih.gov/mesh/D009103 Inflammation https://id.nlm.nih.gov/mesh/D007249 Système nerveux Maladies. Sclérose en plaques. Inflammation (Pathologie) HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Inflammation fast Multiple sclerosis fast Nervous system Degeneration fast Nervous system Diseases fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85090924 http://id.loc.gov/authorities/subjects/sh85090923 http://id.loc.gov/authorities/subjects/sh85088374 http://id.loc.gov/authorities/subjects/sh85066108 https://id.nlm.nih.gov/mesh/D007249Q000503 https://id.nlm.nih.gov/mesh/D009410Q000276 https://id.nlm.nih.gov/mesh/D009103 https://id.nlm.nih.gov/mesh/D007249 |
| title | Neuroinflammation / |
| title_auth | Neuroinflammation / |
| title_exact_search | Neuroinflammation / |
| title_full | Neuroinflammation / edited by Alireza Minagar. |
| title_fullStr | Neuroinflammation / edited by Alireza Minagar. |
| title_full_unstemmed | Neuroinflammation / edited by Alireza Minagar. |
| title_short | Neuroinflammation / |
| title_sort | neuroinflammation |
| topic | Nervous system Diseases. http://id.loc.gov/authorities/subjects/sh85090924 Nervous system Degeneration. http://id.loc.gov/authorities/subjects/sh85090923 Multiple sclerosis. http://id.loc.gov/authorities/subjects/sh85088374 Inflammation. http://id.loc.gov/authorities/subjects/sh85066108 Nervous System Diseases Inflammation physiopathology https://id.nlm.nih.gov/mesh/D007249Q000503 Nerve Degeneration immunology https://id.nlm.nih.gov/mesh/D009410Q000276 Multiple Sclerosis https://id.nlm.nih.gov/mesh/D009103 Inflammation https://id.nlm.nih.gov/mesh/D007249 Système nerveux Maladies. Sclérose en plaques. Inflammation (Pathologie) HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Inflammation fast Multiple sclerosis fast Nervous system Degeneration fast Nervous system Diseases fast |
| topic_facet | Nervous system Diseases. Nervous system Degeneration. Multiple sclerosis. Inflammation. Nervous System Diseases Inflammation physiopathology Nerve Degeneration immunology Multiple Sclerosis Inflammation Système nerveux Maladies. Sclérose en plaques. Inflammation (Pathologie) HEALTH & FITNESS Diseases General. MEDICAL Clinical Medicine. MEDICAL Diseases. MEDICAL Evidence-Based Medicine. MEDICAL Internal Medicine. Multiple sclerosis Nervous system Degeneration Nervous system Diseases |
| url | https://www.sciencedirect.com/science/book/9780128117095 https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1703359 |
| work_keys_str_mv | AT minagaralireza neuroinflammation |